Amid more job cuts, AZ brings on GSK's Dunoyer as business chief

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

AstraZeneca brings on GSK's Dunoyer into newly created role

Amid news of more job cuts and simultaneous new research initiatives, AstraZeneca ($AZN) has appointed Marc Dunoyer to a newly created role--executive vice president of global portfolio and product strategy. Previously, Dunoyer was the global head of rare diseases at GlaxoSmithKline ($GSK). Dunoyer will be responsible for driving business strategy, including business development, mergers and acquisitions, portfolio and product strategies. He will also focus on bolstering the Swedish drug giant's core growth platforms and therapy areas. Release | More

 
Marc Dunoyer--AstraZeneca
Dunoyer will serve as executive vice president of global portfolio and product strategy.
 


 

Jenny Harry--Ondek Limited
Harry will serve as the Australian company's new CEO.

Biotech

> Jenny Harry joined Ondek Limited as the company's CEO. Harry came from Tyrian Diagnostics, where she was CEO and managing director. Release

> Apricus Biosciences has a new CEO: Richard Pascoe, who has held previous positions at Somaxon Pharmaceuticals, ARIAD Pharmaceuticals ($ARIA) and King Pharmaceuticals ($KG). Pascoe will also join the company's board of directors. Story | Release

> Amarantus BioSciences has appointed Mark Benedyk to its board of directors. Benedyk has 18 years of experience as a senior business development executive and consultant to life science companies, and has served as a corporate adviser to Amarantus since 2011. Release

> M. James Barrett and G. Steven Burrill are stepping down from Targacept's board of directors, effective May 31. Barrett and Burrill first joined the company's board in 2002 and 2000, respectively. Release

> Manchester, U.K.-based Phagenesis has appointed Dr. Oern Stuge, former senior executive at Medtronic ($MDT) and Abbott Laboratories ($ABT), as chairman. Release

> Labrys Biologics brought on Marcelo Bigal as its chief medical officer, Michael Chang as VP of project management, Michele Bronson as VP of regulatory and quality, Rafael Escandón as VP of clinical operations and Henry Stern as executive director of CMC. Release

> Rem Laan joined the Sansum Diabetes Research Institute as the organization's executive director. Laan was previously VP of external affairs in Roche's ($RHHBY) North American Diabetes Care business. Release

> F2G, a U.K. antifungal drug discovery and development company, appointed Ian Nicholson as CEO and to a position on the board of directors. Release

> Immunovative brought on Stella M. Sung as the first member of its newly established medical advisory board. Sung is currently the business development officer of Avita Medical. Release

> NeuroVive Pharmaceutical AB appointed Anna Malm Bernstein and Boel Flodgren to its board of directors. Release

> Olivier Pasquier joined France's Cytoo as the life science systems company's chief commercial officer. Release

> 20/20 GeneSystems appointed Joel Kanter as chairman of its board of directors and Raymond Cypess and Lawrence Shulman as board members. Release

> Ignyta brought on Tom Huizinga to its scientific advisory board. Huizinga is a professor and chairman of the rheumatology department at Leiden University Medical Center in the Netherlands. Release

> Sherry Grisewood joined TapImmune's board of directors with 25 years of experience in investment banking, advisory and research-related activities. Release

> Digisonics promoted James Devlin to be president of the cardiology, OB/GYN and radiology company. Release

Pharma

> Ziarco brought on John LaMattina as its strategic adviser. LaMattina was formerly president of Pfizer ($PFE) Global R&D. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.